NCT05134792View on ClinicalTrials.gov

Effect of Pre-emptive Intravenous Immunoglobulin (IVIG) on the Incidence of Septic Episodes in Pediatric Burn Patients

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 10, 2021

Primary Completion Date

July 16, 2022

Study Completion Date

July 16, 2022

Conditions
Burn Shock
Interventions
DRUG

intravenous immunoglobulin

All pediatric burn patients allocated in group intra venous immunoglobulin admitted will receive 200 mg/kg IVIG once after their initial resuscitation before 48 hours passes of burn incident.

Trial Locations (1)

Unknown

Cairo University, Cairo

All Listed Sponsors
lead

Cairo University

OTHER

NCT05134792 - Effect of Pre-emptive Intravenous Immunoglobulin (IVIG) on the Incidence of Septic Episodes in Pediatric Burn Patients | Biotech Hunter | Biotech Hunter